vs

Side-by-side financial comparison of Falcon's Beyond Global, Inc. (FBYD) and NovaBay Pharmaceuticals, Inc. (NBY). Click either name above to swap in a different company.

Falcon's Beyond Global, Inc. is the larger business by last-quarter revenue ($6.6M vs $4.8M, roughly 1.4× NovaBay Pharmaceuticals, Inc.). Falcon's Beyond Global, Inc. runs the higher net margin — -4.5% vs -25.5%, a 21.0% gap on every dollar of revenue. On growth, Falcon's Beyond Global, Inc. posted the faster year-over-year revenue change (383.5% vs 126.1%). NovaBay Pharmaceuticals, Inc. produced more free cash flow last quarter ($-1.7M vs $-4.3M). Over the past eight quarters, Falcon's Beyond Global, Inc.'s revenue compounded faster (108.4% CAGR vs 42.5%).

500 Global is an early-stage venture fund and seed accelerator founded in 2010 by Dave McClure and Christine Tsai. The fund admitted a first "class" of twelve startups to its incubator office in Mountain View, California in February 2011. They expanded to a second class of 21 in June 2011 and a third class of 34 in October 2011. 500 Global has $2.3 billion in assets under management (AUM) as of March 2024.

NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on products for eye care. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. and NeutroPhase, used in treatment of Necrotizing Fasciitis

FBYD vs NBY — Head-to-Head

Bigger by revenue
FBYD
FBYD
1.4× larger
FBYD
$6.6M
$4.8M
NBY
Growing faster (revenue YoY)
FBYD
FBYD
+257.4% gap
FBYD
383.5%
126.1%
NBY
Higher net margin
FBYD
FBYD
21.0% more per $
FBYD
-4.5%
-25.5%
NBY
More free cash flow
NBY
NBY
$2.7M more FCF
NBY
$-1.7M
$-4.3M
FBYD
Faster 2-yr revenue CAGR
FBYD
FBYD
Annualised
FBYD
108.4%
42.5%
NBY

Income Statement — Q4 FY2025 vs Q4 FY2024

Metric
FBYD
FBYD
NBY
NBY
Revenue
$6.6M
$4.8M
Net Profit
$-296.0K
$-1.2M
Gross Margin
65.2%
Operating Margin
-30.9%
-37.2%
Net Margin
-4.5%
-25.5%
Revenue YoY
383.5%
126.1%
Net Profit YoY
97.5%
70.5%
EPS (diluted)
$-0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FBYD
FBYD
NBY
NBY
Q4 25
$6.6M
Q3 25
$4.1M
Q2 25
$2.5M
Q1 25
$1.7M
Q4 24
$1.4M
$4.8M
Q3 24
$2.1M
$0
Q2 24
$1.8M
$2.4M
Q1 24
$1.5M
$2.6M
Net Profit
FBYD
FBYD
NBY
NBY
Q4 25
$-296.0K
Q3 25
$-10.4M
Q2 25
$25.1M
Q1 25
$-8.1M
Q4 24
$-11.9M
$-1.2M
Q3 24
$39.3M
$-1.2M
Q2 24
$8.0M
$-1.6M
Q1 24
$114.0M
$-3.2M
Gross Margin
FBYD
FBYD
NBY
NBY
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
65.2%
Q3 24
Q2 24
66.3%
Q1 24
68.2%
Operating Margin
FBYD
FBYD
NBY
NBY
Q4 25
-30.9%
Q3 25
-90.9%
Q2 25
-53.0%
Q1 25
-371.1%
Q4 24
-335.6%
-37.2%
Q3 24
-118.9%
Q2 24
-195.9%
-67.4%
Q1 24
-350.5%
-87.1%
Net Margin
FBYD
FBYD
NBY
NBY
Q4 25
-4.5%
Q3 25
-256.8%
Q2 25
985.2%
Q1 25
-473.8%
Q4 24
-871.7%
-25.5%
Q3 24
1899.5%
Q2 24
446.5%
-66.0%
Q1 24
7521.4%
-122.2%
EPS (diluted)
FBYD
FBYD
NBY
NBY
Q4 25
$-0.01
Q3 25
$-0.13
Q2 25
$0.30
Q1 25
$-0.13
Q4 24
$-0.25
Q3 24
$0.39
$-1.92
Q2 24
$0.00
$-1.37
Q1 24
$1.27
$-29.95

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FBYD
FBYD
NBY
NBY
Cash + ST InvestmentsLiquidity on hand
$1.9M
$430.0K
Total DebtLower is stronger
$15.6M
Stockholders' EquityBook value
$11.9M
$-129.0K
Total Assets
$66.7M
$3.4M
Debt / EquityLower = less leverage
1.31×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FBYD
FBYD
NBY
NBY
Q4 25
$1.9M
Q3 25
$4.3M
Q2 25
$26.1M
Q1 25
$1.1M
Q4 24
$825.0K
$430.0K
Q3 24
$828.0K
$776.0K
Q2 24
$1.7M
$751.0K
Q1 24
$1.1M
$1.8M
Total Debt
FBYD
FBYD
NBY
NBY
Q4 25
$15.6M
Q3 25
Q2 25
Q1 25
Q4 24
$41.2M
Q3 24
$10.3M
Q2 24
$15.7M
Q1 24
$15.1M
Stockholders' Equity
FBYD
FBYD
NBY
NBY
Q4 25
$11.9M
Q3 25
$9.2M
Q2 25
$414.0K
Q1 25
$-11.6M
Q4 24
$-9.0M
$-129.0K
Q3 24
$-1.4M
$1.1M
Q2 24
$-44.7M
$-617.0K
Q1 24
$-61.7M
$160.0K
Total Assets
FBYD
FBYD
NBY
NBY
Q4 25
$66.7M
Q3 25
$66.8M
Q2 25
$89.2M
Q1 25
$56.7M
Q4 24
$61.2M
$3.4M
Q3 24
$66.5M
$3.9M
Q2 24
$65.9M
$3.9M
Q1 24
$67.8M
$5.4M
Debt / Equity
FBYD
FBYD
NBY
NBY
Q4 25
1.31×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FBYD
FBYD
NBY
NBY
Operating Cash FlowLast quarter
$-4.3M
$-1.7M
Free Cash FlowOCF − Capex
$-4.3M
$-1.7M
FCF MarginFCF / Revenue
-66.0%
-35.4%
Capex IntensityCapex / Revenue
0.3%
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FBYD
FBYD
NBY
NBY
Q4 25
$-4.3M
Q3 25
$-13.3M
Q2 25
$-7.9M
Q1 25
$945.0K
Q4 24
$-3.8M
$-1.7M
Q3 24
$-2.4M
$-2.4M
Q2 24
$-2.6M
$-1.4M
Q1 24
$-3.8M
$-2.0M
Free Cash Flow
FBYD
FBYD
NBY
NBY
Q4 25
$-4.3M
Q3 25
$-13.4M
Q2 25
Q1 25
$853.0K
Q4 24
$-3.8M
$-1.7M
Q3 24
$-2.4M
Q2 24
$-2.6M
Q1 24
$-3.8M
$-2.0M
FCF Margin
FBYD
FBYD
NBY
NBY
Q4 25
-66.0%
Q3 25
-329.6%
Q2 25
Q1 25
49.9%
Q4 24
-278.7%
-35.4%
Q3 24
-114.9%
Q2 24
-145.6%
Q1 24
-248.8%
-75.3%
Capex Intensity
FBYD
FBYD
NBY
NBY
Q4 25
0.3%
Q3 25
1.0%
Q2 25
0.0%
Q1 25
5.4%
Q4 24
0.1%
0.1%
Q3 24
0.2%
Q2 24
0.1%
0.0%
Q1 24
0.3%
0.1%
Cash Conversion
FBYD
FBYD
NBY
NBY
Q4 25
Q3 25
Q2 25
-0.31×
Q1 25
Q4 24
Q3 24
-0.06×
Q2 24
-0.33×
Q1 24
-0.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FBYD
FBYD

Segment breakdown not available.

NBY
NBY

Other$2.4M51%
Total Product Revenue$2.3M49%

Related Comparisons